haloperidol has been researched along with g(m1) ganglioside in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (21.43) | 18.7374 |
| 1990's | 9 (64.29) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruno, JP; Hadjiconstantinou, M; Neff, NH; Weihmuller, FB | 2 |
| de Beaurepaire, R; Freed, WJ; Greenberg, JA; Schwarz, SS; Spoor, HE | 1 |
| Andreassen, OA; Jørgensen, HA | 1 |
| Frussa-Filho, R; Palermo-Neto, J; Vital, MA | 2 |
| Augustin, W; Sabel, BA; Schröder, H; Schröder, U | 1 |
| Mahadik, SP; Mukherjee, S | 1 |
| Sabel, BA; Schroeder, H; Schroeder, U | 1 |
| De Lucia, R; Flório, JC; Frussa-Filho, R; Palermo-Neto, J; Tufik, S; Vital, MA | 1 |
| Ferrari, G; Minozzi, MC; Silvestrini, B; Zanellato, AM | 1 |
| Frussa-Filho, R; Palermo-Neto, J; Vital, MB | 1 |
| Frussa-Filho, R; Palermo-Neto, J; Perry, JC; Tufik, S; Vital, MA | 1 |
| Kasahara, R; Sobue, K; Suzuki, K; Yamamoto, N | 1 |
14 other study(ies) available for haloperidol and g(m1) ganglioside
| Article | Year |
|---|---|
Continued administration of GM1 ganglioside is required to maintain recovery from neuroleptic-induced sensorimotor deficits in MPTP-treated mice.
Topics: Animals; Brain Diseases; Catalepsy; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; G(M1) Ganglioside; Haloperidol; Injections, Intravenous; Male; Mice; Motor Activity; Movement Disorders; MPTP Poisoning; Orientation; Receptors, Dopamine; Receptors, Dopamine D2; Up-Regulation | 1989 |
Administration of GM1 ganglioside eliminates neuroleptic-induced sensorimotor deficits in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Behavior, Animal; Corpus Striatum; Dopamine; G(M1) Ganglioside; Haloperidol; Male; Mice; Movement Disorders; Pyridines | 1988 |
Embryonic substantia nigra grafts. Factors controlling behavioral efficacy and reinnervation of the host striatum.
Topics: Animals; Apomorphine; Cerebral Cortex; Cerebral Ventricles; Embryo, Mammalian; Estradiol; Female; G(M1) Ganglioside; Haloperidol; Motor Activity; Nerve Regeneration; Ovariectomy; Rats; Substantia Nigra | 1987 |
GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats.
Topics: Animals; Excitatory Amino Acid Antagonists; Female; G(M1) Ganglioside; Haloperidol; Rats; Rats, Sprague-Dawley; Stereotyped Behavior | 1994 |
Effects of monosialoganglioside on dopaminergic supersensitivity.
Topics: Animals; G(M1) Ganglioside; Haloperidol; Male; Rats; Rats, Wistar; Receptors, Dopamine; Stereotyped Behavior | 1995 |
Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding.
Topics: Animals; Corpus Striatum; Dose-Response Relationship, Drug; G(M1) Ganglioside; Gangliosides; Haloperidol; Male; Motor Activity; Rats; Rats, Wistar; Receptors, Dopamine D2; Spiperone | 1994 |
Monosialoganglioside cotreatment prevents haloperidol treatment-associated loss of cholinergic enzymes in rat brain.
Topics: Animals; Antipsychotic Agents; Cerebral Cortex; Choline O-Acetyltransferase; Corpus Striatum; G(M1) Ganglioside; Haloperidol; Hippocampus; Male; Rats; Rats, Sprague-Dawley | 1995 |
The role of striatal glutamatergic system in haloperidol-induced dopamine receptor supersensitivity and effects of monosialoganglioside GM1.
Topics: Animals; Aspartic Acid; Dopamine Antagonists; G(M1) Ganglioside; Glutamic Acid; Haloperidol; Male; Neostriatum; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Glutamate; Spiperone | 1997 |
Effects of haloperidol and GM1 ganglioside treatment on striatal D2 receptor binding and dopamine turnover.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Antagonists; Drug Administration Schedule; Drug Synergism; G(M1) Ganglioside; Haloperidol; Kinetics; Male; Rats; Rats, Wistar; Receptors, Dopamine D2; Spiperone; Tritium | 1998 |
GM1, like IGF-I and GDNF, prevents neuronal apoptosis.
Topics: Animals; Apoptosis; Cells, Cultured; Cerebellum; Chlorpromazine; G(M1) Ganglioside; Glial Cell Line-Derived Neurotrophic Factor; Haloperidol; Insulin-Like Growth Factor I; Nerve Growth Factors; Nerve Tissue Proteins; Neurons; Neuroprotective Agents | 1998 |
Monosialoganglioside increased the in vivo affinity of D2 receptors for apomorphine in supersensitive rats.
Topics: Animals; Antipsychotic Agents; Apomorphine; Corpus Striatum; G(M1) Ganglioside; Haloperidol; Kinetics; Metoclopramide; Rats; Receptors, Dopamine D2; Stereotyped Behavior; Substance Withdrawal Syndrome | 1998 |
Kinetic analysis of GM1 effects on haloperidol-induced dopaminergic supersensitivity.
Topics: Animals; Dopamine Antagonists; G(M1) Ganglioside; Haloperidol; Kinetics; Male; Rats; Rats, Wistar; Receptors, Dopamine D2; Stereotyped Behavior | 1999 |
Monosialoganglioside (GM1) attenuates the behavioural effects of long-term haloperidol administration in supersensitive rats.
Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Dopamine Agonists; Dopamine Antagonists; Drug Administration Schedule; Drug Interactions; G(M1) Ganglioside; Haloperidol; Immobilization; Locomotion; Male; Rats; Rats, Wistar; Stereotyped Behavior; Substance Withdrawal Syndrome; Time Factors | 2004 |
The σ1 receptor regulates accumulation of GM1 ganglioside-enriched autophagosomes in astrocytes.
Topics: Animals; Antipsychotic Agents; Astrocytes; Autophagosomes; Cells, Cultured; Cerebral Cortex; Dose-Response Relationship, Drug; Ethylenediamines; G(M1) Ganglioside; Haloperidol; Intracellular Space; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D4; Receptors, sigma | 2017 |